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Despite the improved prognosis for many cancer patients, the survival for those with Glioblastoma 
multiforme (GBM) remains dismal. Even with aggressive intervention, including resection, radiation, 
and chemotherapy, the overall 2-year survival rate is only 25% in the most optimistic series, and 5-year 
survival rates are consistently in the low single digits (1, 2). Therefore, it is evident that novel thera-
peutic paradigms are necessary to overcome the inherent limitations of conventional treatments. Emerg-
ing data offer encouraging evidence that patient-speciﬁ  c therapies tailored to the unique biology of an 
individual’s GBM may improve clinical outcomes.
EGFR is a receptor tyrosine kinase (RTK) that is commonly overexpressed in GBMs, and this 
overexpression typically occurs as a result of gene ampliﬁ  cation. The EGFR-mediated signal transduction 
results in activation of a number of downstream pathways including PI3K-AKT and RAS-MAPK, 
inhibiting apoptosis and driving proliferation. Several studies have demonstrated variability of gene 
expression in different sets of GBMs (3–5). In particular, tumors expressing EGFR, which is associated 
with a particularly poor prognosis, can clearly be identiﬁ  ed by microarray expression analysis (5). 
Alternatively, deletion within the EGFR coding sequence can result in the expression of a truncated, 
mutant EGFR protein that signals constitutively. With the development of molecular inhibitors target-
ing multiple pathways, such as EGFR, the combination of expression analysis and mutation status may 
enable the development of therapeutic modalities tailored to individual disease characteristics.
To this end, Mellinghoff and colleagues investigated the molecular determinants of GBM respon-
siveness to EGFR kinase inhibitors (6). In this study, the authors sequenced the kinase domains of EGFR 
and human EGFR type 2 (Her2/neu). They also analyzed the expression of EGFR, EGFR deletion 
mutant variant III (EGFRvIII), and phosphatase and tensin homolog (PTEN) in recurrent malignant 
gliomas from 26 patients receiving EGFR kinase inhibitor (EGFR-ki) therapy. Twenty-seven percent 
of patients (7/26) responded to EGFR-ki therapy by showing tumor shrinkage of at least 25%. All oth-
ers had rapid disease progression. There were no mutations in EGFR or Her2/neu detected. Coexpres-
sion of EGFRvIII and PTEN, however, was signiﬁ  cantly associated with clinical responsiveness 
(P   0.001; OR 51). These ﬁ  ndings were validated in 33 GBM patients undergoing similar treatment 
at a different institution (P = 0.001, OR 40). Furthermore, in vitro coexpression of EGFRvIII and PTEN 
by GBM cells was associated with sensitivity to erlotinib. The authors concluded that the presence of 
EGFRvIII and PTEN may serve as predictive markers for treatment success in GBM patients receiving 
EGFR kinase inhibitors.
The authors have elucidated rational therapeutic targets, thereby enhancing clinical applicability and 
adding to an increasing body of literature supporting the utility of expression proﬁ  ling in GBM patient 
stratiﬁ  cation (7, 8). From their ﬁ  ndings it is apparent that adjuvant regimens should not be uniform, 
and that choosing the most efﬁ  cacious agent for each individual may require routine expression analy-
sis to target susceptible molecular pathways. For instance, expression analysis could be conducted 
immediately after resection in multiple biopsy samples of core and invasive tumor regions, perhaps 
identiﬁ  ed on preoperative magnetic resonance imaging (MRI). Implementing expression analysis as a 222
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standard clinical test, however, will require 
signiﬁ  cant changes in the way clinicians approach 
GBM treatment, as well as the development 
of substantial infrastructure for rapid, high-
throughput expression and mutation analysis. The 
subsequent challenge of interpreting this data will 
require an expansion of expertise from academic 
studies to wider clinical practice. Despite these 
obstacles, it is vital to take into account the genetic 
mutations present in each patient’s tumor before 
chemotherapeutic agents that target molecular 
pathways can ever be expected to achieve maximal 
clinical efﬁ  cacy. In conclusion, it is important to 
consider GBMs as a group of related but geneti-
cally distinct tumor cells, and capitalize on this 
knowledge by using therapies that target all 
populations present within the lesion.
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